Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems Nicola Flaum 1, Juan W Valle 1,2, Wasat Mansoor 1, Mairéad G McNamara 1,2 1 Department of Medical Oncology, The Christie NHS Foundation Manchester, UK – 2 University of Manchester, Institute of Cancer Sciences, Manchester, UK – Corresponding author Dr Mairéad G McNamara Department of Medical Oncology The Christie NHS Foundation of Manchester, Institute of Cancer Sciences Manchester M20 4BX UK Tel: 0161 446 8106 Fax: 0161 446 3468 Keywords: Neuroendocrine trial, pancreatic, carcinoid, metastatic, targeted therapy, everolimus, mTOR inhibitor
Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems Nicola Flaum 1, Juan W Valle 1,2, Wasat Mansoor 1, Mairéad G McNamara 1,2 1 – Department of Medical Oncology, The Christie NHS Foundation Manchester, UK 2 – University of Manchester, Institute of Cancer Sciences, Manchester, UK Corresponding author Dr Mairéad G McNamara Department of Medical Oncology The Christie NHS Foundation of Manchester, Institute of Cancer Sciences Manchester M20 4BX UK Tel: 0161 446 8106 Fax: 0161 446 3468 Keywords: Neuroendocrine pancreatic, carcinoid, metastatic, targeted therapy, everolimus, mTOR inhibitor trial,
2016_07_29_Future_Oncology_Everolimus_review_manuscript.docx